Patents by Inventor Melody A. Swartz
Melody A. Swartz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240044896Abstract: Aspects of the disclosure are directed to methods, systems, and compositions for detecting antibodies capable of binding to angiotensin II. Certain aspects comprise detection of antibodies capable of binding to angiotensin II in a sample from a subject, where the subject has or has had a coronavirus infection, such as a SARS-CoV-2 infection. Also disclosed are vaccine compositions comprising a portion of SARS-CoV-2 Spike protein, where such compositions do not induce generation of angiotensin II-binding antibodies.Type: ApplicationFiled: December 9, 2021Publication date: February 8, 2024Applicant: The University of ChicagoInventors: Melody SWARTZ, Priscilla BRIQUEZ, Jeffrey HUBBELL
-
Publication number: 20230377764Abstract: The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with an antibody that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.Type: ApplicationFiled: February 3, 2023Publication date: November 23, 2023Applicant: The University of ChicagoInventors: Jeffrey A. HUBBELL, Jun ISHIHARA, Ako ISHIHARA, Kazuto FUKUNAGA, Melody SWARTZ
-
Patent number: 11574747Abstract: The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with an antibody that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.Type: GrantFiled: April 20, 2018Date of Patent: February 7, 2023Assignee: The University of ChicagoInventors: Jeffrey A. Hubbell, Jun Ishihara, Ako Ishihara, Kazuto Fukunaga, Melody Swartz
-
Publication number: 20220168448Abstract: An encoding/decoding apparatus and method using a low-density parity-check code (LDPC code) is disclosed. Basic column group information, serving as a set of information regarding positions of rows with weight 1, is extracted from a reference column in each column group of a predetermined parity-check matrix. Column group information transforms the positions of rows with weight 1 into positions whose lengths are within a required parity length. A parity-check matrix is generated according to the generated column group information. Data is enclosed or decoded based on the generated parity-check matrix.Type: ApplicationFiled: July 2, 2021Publication date: June 2, 2022Inventors: Jeffrey A. HUBBELL, Conlin P. O'NEIL, Melody SWARTZ, Diana VELLUTO, André Van Der Vlies
-
Publication number: 20220047700Abstract: The present invention concerns methods and compositions for evoking protective immune responses against pathogen infection or cancer. In certain embodiments, the methods and compositions comprise a lymphangiogenesis inducer and an antigen.Type: ApplicationFiled: November 5, 2021Publication date: February 17, 2022Applicant: The University of ChicagoInventors: Jeffrey A. Hubbell, Melody A. Swartz, Shann S. Yu, Efthymia Vokali, Manuel Fankhauser, Sachiko Hirosue, Priscilla S. Briquez, Maria Broggi, Lambert Potin, Maria Stella Sasso
-
Patent number: 10980877Abstract: The present invention concerns methods and compositions for evoking protective immune responses against pathogen infection or cancer. In certain embodiments, the methods and compositions comprise a lymphangiogenesis inducer and an antigen.Type: GrantFiled: April 28, 2017Date of Patent: April 20, 2021Assignee: The University of ChicagoInventors: Melody A. Swartz, Jeffrey A. Hubbell, Shann Yu, Efthymia Vokali, Manuel Fankhauser, Sachiko Hirosue, Priscilla S. Briquez, Maria Broggi, Lambert Potin, Maria Stella Sasso
-
Publication number: 20210094995Abstract: The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with a cytokine that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.Type: ApplicationFiled: March 5, 2019Publication date: April 1, 2021Inventors: Jeffrey A. HUBBELL, Jun ISHIHARA, Ako ISHIHARA, Koichi SASAKI, Melody SWARTZ, Aslan MANSUROV
-
Publication number: 20200123228Abstract: The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with an antibody that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.Type: ApplicationFiled: April 20, 2018Publication date: April 23, 2020Inventors: Jeffrey A. HUBBELL, Jun ISHIHARA, Ako ISHIHARA, Kazuto FUKUNAGA, Melody SWARTZ
-
Publication number: 20200000936Abstract: An encoding/decoding apparatus and method using a low-density parity-check code (LDPC code) is disclosed. Basic column group information, serving as a set of information regarding positions of rows with weight 1, is extracted from a reference column in each column group of a predetermined parity-check matrix. Column group information transforms the positions of rows with weight 1 into positions whose lengths are within a required parity length. A parity-check matrix is generated according to the generated column group information. Data is enclosed or decoded based on the generated parity-check matrix.Type: ApplicationFiled: July 1, 2019Publication date: January 2, 2020Inventors: James Brandon DIXON, Jeffrey A. Hubbell, Conlin P. O'Neil, Melody Swartz, Diana Velluto
-
Patent number: 10335499Abstract: Block copolymers containing charged blocks or chemical moieties sensitive to oxidation or hydrolysis have been developed. We describe the use of such block copolymers in supramolecular structures, e.g., micelles or vesicles, and pharmaceutical compositions and in methods of preparing the supramolecular structures and pharmaceutical compositions. The invention is particularly useful for the delivery of pharmaceutical agents, e.g., nucleic acids, to cells.Type: GrantFiled: February 5, 2016Date of Patent: July 2, 2019Assignee: École Polytechnique Fédérale de Lausanne (EPFL)Inventors: James Brandon Dixon, Jeffrey A. Hubbell, Conlin P. O'Neil, Melody Swartz, Diana Velluto
-
Publication number: 20190099485Abstract: The present invention concerns methods and compositions for evoking protective immune responses against pathogen infection or cancer. In certain embodiments, the methods and compositions comprise a lymphangiogenesis inducer and an antigen.Type: ApplicationFiled: April 28, 2017Publication date: April 4, 2019Inventors: Melody A. Swartz, Jeffrey A. Hubbell, Shann Yu, Efthymia Vokali, Manuel Fankhauser, Sachiko Hirosue, Priscilla S. Briquez, Maria Broggi, Lambert Potin, Maria Stella Sasso
-
Publication number: 20160256569Abstract: Block copolymers containing charged blocks or chemical moieties sensitive to oxidation or hydrolysis have been developed. We describe the use of such block copolymers in supramolecular structures, e.g., micelles or vesicles, and pharmaceutical compositions and in methods of preparing the supramolecular structures and pharmaceutical compositions. The invention is particularly useful for the delivery of pharmaceutical agents, e.g., nucleic acids, to cells.Type: ApplicationFiled: February 5, 2016Publication date: September 8, 2016Inventors: James Brandon DIXON, Jeffrey A. HUBBELL, Conlin P. O'NEIL, Melody SWARTZ, Diana VELLUTO
-
Patent number: 9271929Abstract: An encoding/decoding apparatus and method using a low-density parity-check code (LDPC code) is disclosed. Basic column group information, serving as a set of information regarding positions of rows with weight 1, is extracted from a reference column in each column group of a predetermined parity-check matrix. Column group information transforms the positions of rows with weight 1 into positions whose lengths are within a required parity length. A parity-check matrix is generated according to the generated column group information. Data is encoded or decoded based on the generated parity-check matrix.Type: GrantFiled: November 24, 2009Date of Patent: March 1, 2016Assignee: École Polytechnique Fédérale de Lausanne (EPFL)Inventors: James Brandon Dixon, Jeffrey A. Hubbell, Conlin P. O'Neil, Melody Swartz, Diana Velluto
-
Patent number: 8592364Abstract: Chemokines may be administered to a patient for immunotolerization. Chemokines include CCL19 and CCL21. Materials and methods for accomplishing tolerization and described.Type: GrantFiled: February 10, 2011Date of Patent: November 26, 2013Assignee: Ecole Polytechnique Federale de Lausanne (“EPFL”)Inventors: Melody A. Swartz, Jeffrey A. Hubbell, Alice A. Tomei, Jacqueline D. Shields, Iraklis Kourtis
-
Patent number: 8323696Abstract: Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described.Type: GrantFiled: August 29, 2008Date of Patent: December 4, 2012Assignee: Ecole Polytechnique Federale de LausanneInventors: Jeffrey A. Hubbell, Conlin P. O'Neil, Sai T. Reddy, Melody A. Swartz, Diana Velluto, André van der Vlies, Eleonora Simeoni
-
Patent number: 8021689Abstract: Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics.Type: GrantFiled: February 19, 2007Date of Patent: September 20, 2011Assignee: Ecole Polytechnique Federale de Lausanne (“EPFL”)Inventors: Sai T. Reddy, Jeffrey A. Hubbell, Melody A. Swartz, André van der Vlies
-
Publication number: 20110223217Abstract: An encoding/decoding apparatus and method using a low-density parity-check code (LDPC code) is disclosed. Basic column group information, serving as a set of information regarding positions of rows with weight 1, is extracted from a reference column in each column group of a predetermined parity-check matrix. Column group information transforms the positions of rows with weight 1 into positions whose lengths are within a required parity length. A parity-check matrix is generated according to the generated column group information. Data is encoded or decoded based on the generated parity-check matrix.Type: ApplicationFiled: November 24, 2009Publication date: September 15, 2011Applicant: Ecole Polytechnique Federale de Lausanne (EPFL)Inventors: James Brandon Dixon, Jeffrey A. Hubbell, Conlin P. O'Neil, Melody Swartz, Diana Velluto
-
Publication number: 20110206759Abstract: Chemokines may be administered to a patient for immunotolerization. Chemokines include CCL19 and CCL21. Materials and methods for accomplishing tolerization and described.Type: ApplicationFiled: February 10, 2011Publication date: August 25, 2011Inventors: Melody A. Swartz, Jeffrey A. Hubbell, Alice A. Tomei, Jacqueline D. Shields, Iraklis Kourtis
-
Publication number: 20100055189Abstract: Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described.Type: ApplicationFiled: August 29, 2008Publication date: March 4, 2010Inventors: Jeffrey A. Hubbell, Conlin P. O'Neil, Sai T. Reddy, Melody A. Swartz, Diana Velluto, Andre van Der Vlies, Eleonora Simeoni
-
Publication number: 20080031899Abstract: Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics.Type: ApplicationFiled: February 19, 2007Publication date: February 7, 2008Inventors: Sai Reddy, Jeffrey Hubbell, Melody Swartz, Andre Vlies